The Clinical Benefit and Necessity of Neoadjuvant Immunotherapy for PD-L1–Negative Resectable NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Lung Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Is neoadjuvant immunotherapy necessary in patients with programmed death ligand 1 expression-negative resectable non-small cell lung cancer? A systematic review and meta-analysis
Lung Cancer 2024 May 01;191(2024)107799, SL Zhang, Y Tian, J Yu, JH Zhang, L Sun, LT Huang, JT Ma, CB HanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.